ClinicalTrials.gg
CompletedNCT02656485Updated Apr 5, 2017Results posted

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

A Phase 1/2 interventional study of B244 and Placebo in Acne Vulgaris, sponsored by AOBiome LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by AOBiome LLC · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Aug 2015, registered Jan 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
241st of 353
36 · median 78
Started
2015
with 24 others
Phase 1/2
11 of 373
2 open now
Registered
184th of 373
by date

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 241st largest by enrollment of the 353 interventional ones that give a count, is one of 25 that started in 2015, is one of 11 in phase 1/2, and was the 184th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

This is a single center, randomized, double-blind, placebo-controlled study in subjects with acne vulgaris.

Read the detailed description

After a screening visit and a one-week washout (if applicable), three sequential ascending doses of the study drug will be applied twice-daily (BID) for 14 days in three groups of subjects. Each group of subjects will be randomized to receive the planned doses of B244 or placebo BID

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects ≥18 and ≤45 years of age
  2. In good general health as determined by a thorough medical history and physical examination, (ECG), vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without abnormalities, including hematology, clinical chemistry and urinalysis.
  3. Clinical diagnosis of facial acne vulgaris defined as:

    • ≥105 inflammatory lesions
    • ≥10 non-inflammatory lesions
    • IGA ≥2
  4. Willing to refrain from using any treatments, other than the product, including antibiotics, for acne present on the face. Topical acne treatments that do not have significant or measurable systemic absorption (e.g., benzoyl peroxide, salicylic acid) are allowed for treatment of acne of the back, shoulders and chest only.
  5. Ability to comprehend and comply with procedures
  6. Agree to commit to participate in the current protocol
  7. Provide written prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating or who are trying to conceive
  2. Female subjects with a positive urine β-human chorionic gonadotropin (β-hCG) test at screening or positive β-hCG urine at pre-dose
  3. Any abnormality identified on the screening history, physical or laboratory examinations, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
  4. Any skin condition which may interfere with the evaluation of safety or of acne vulgaris (e.g., rosacea; seborrheic dermatitis; perioral dermatitis; -induced acne or folliculitis)
  5. Use of tanning booths or excessive sun exposure, in the opinion of the investigator
  6. Active cystic acne or acne congoblata, acne fulminans, and secondary acne
  7. Two or more active nodular lesions
  8. Treatment with over-the-counter topical medications for the treatment of acne vulgaris including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid on the face within 2 weeks prior to baseline
  9. Treatment with systemic corticosteroids (including intranasal and inhaled corticosteroids) within 4 weeks prior to baseline
  10. Treatment with systemic antibiotics or systemic anti-acne drugs or systemic anti-inflammatory drugs within 4 weeks prior to baseline
  11. Prescription topical retinoid use on the face within 4 weeks of baseline (e.g., tretinoin, tazarotene, adapalene)
  12. Treatment with hormonal therapy or dose change to hormonal therapy within 12 weeks prior to baseline. Dose and frequency of use of any hormonal therapy started more than 12 weeks prior to baseline must remain unchanged throughout the study. Hormonal therapies include, but are not limited to, estrogenic and progestational agents such as pills.
  13. Use of androgen receptor blockers (such as spironolactone or flutamide)
  14. Oral retinoid use (e.g., isotretinoin) within 12 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline
  15. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the 8 weeks of the first dose or during the study
  16. A positive urine drug screen for drugs of abuse, including alcohol or positive urine cotinine (≥300 ng/mL for cotinine) at the screening visit or at entry to the clinic (Note: urine cotinine required at screening visit only)
  17. Treatment with any drug within 30 days or 5 half-lives (whichever is longer) prior to the beginning of the screening period (this includes investigational formulations of marketed products, inhaled and topical drugs)
  18. to B244 or its components
  19. Blood collection of greater than 500 mL within 56 days prior to screening
  20. Seropositive for (HIV) at screening
  21. Positive for virus surface antigen (HBsAg) or positive virus antibody (HCV Ab) at screening
  22. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Dose I

    B244 Dose 1 (dose level \[cells/mL\] 20,000,000,000)

    Drug: B244 · Drug: Placebo

  • Experimental
    Dose II

    B244 Dose 2 (dose level \[cells/mL\] 40,000,000,000)

    Drug: B244 · Drug: Placebo

  • Experimental
    Dose III

    B244 Dose 3 (dose level \[cells/mL\] 80,000,000,000)

    Drug: B244 · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo to Match B244

    Drug: B244

Interventions

  • DrugB244

    10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

  • DrugPlacebo

    10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

06

What researchers measure

Primary outcomes

  1. Safety (Number of Participants With Treatment Related Adverse Events)

    Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses

    Time frame: 4 weeks

Secondary outcomes

  1. Efficacy

    Absolute Change from Baseline in Total Number of Lesions

    Time frame: Baseline and 4 weeks

07

Results

Posted Apr 5, 2017

Participant flow

Participant flow — Overall Study
MilestoneDose IDose IIDose IIIPlacebo
Started9999
Completed7677
Not completed2322

Outcome measures

PrimarySafety (Number of Participants With Treatment Related Adverse Events)

Number of participants with treatment related adverse events as assessed by physical examination, vital signs, clinical laboratory values, local skin responses

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Safety (Number of Participants With Treatment Related Adverse Events)
ParticipantsDose IDose IIDose IIIPlacebo
Safety (Number of Participants With Treatment Related Adverse Events)4122
SecondaryEfficacy

Absolute Change from Baseline in Total Number of Lesions

Time frame:
Baseline and 4 weeks
Reported as:
Mean · Lesions
Efficacy
LesionsPooled Active DosesPlacebo
Efficacy-9.6 ± 12.09-6.7 ± 10.66

Adverse events

Collected over Subjects were monitored for Adverse Events from Study Day 1 through Day 28 of the study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose I0/9 (0%)0/9 (0%)4/9 (44.4%)
Dose II0/9 (0%)0/9 (0%)1/9 (11.1%)
Dose III0/9 (0%)0/9 (0%)2/9 (22.2%)
Placebo0/9 (0%)0/9 (0%)2/9 (22.2%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDose IDose IIDose IIIPlacebo
NasopharyngitisInfections and infestations1/90/90/90/9
Application Site PainGeneral disorders1/90/90/90/9
HeadacheNervous system disorders1/90/90/90/9
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/90/90/90/9
MigraineNervous system disorders1/90/90/90/9
Urinary Tract infectionInfections and infestations1/90/90/90/9
PyrexiaGeneral disorders1/90/90/90/9
VomitingGastrointestinal disorders1/90/90/90/9
Arthropod StingInjury, poisoning and procedural complications0/91/90/90/9
Streptococcal InfectionInfections and infestations0/91/90/90/9

Baseline characteristics

All subjects were adult men or women, between the ages of 18 and 45 years.

Age, Continuous
Age, Continuous(years)Dose IDose IIDose IIIPlaceboTotal
Mean29.4 ± 10.026 ± 8.229.2 ± 4.831.7 ± 10.129.1 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Dose IDose IIDose IIIPlaceboTotal
Female757928
Male24208
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose IDose IIDose IIIPlaceboTotal
American Indian or Alaska Native01001
Asian10012
Native Hawaiian or Other Pacific Islander00000
Black or African American11327
White325414
More than one race12003
Unknown or Not Reported33129
08

Study locations

1 site
  • Stephens Associates
    Richardson, Texas 75081, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Mar 2016, 6 months.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

Of 13 phase 1/2 interventional studies under Acne Vulgaris, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2016
First posted
Jan 15, 2016
StartActual
Aug 5, 2015
Primary completionActual
Mar 1, 2016
CompletionActual
Jul 15, 2016
Results first posted
Apr 5, 2017
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02656485
Lead sponsor
AOBiome LLC
Responsible party
Sponsor
First posted
Jan 15, 2016
Start date
Aug 5, 2015
Primary completion
Mar 1, 2016
Completion
Jul 15, 2016
Results posted
Apr 5, 2017
Last update
Apr 5, 2017

Study contacts

Peter Hino, MD
principal investigator · Stephens Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitrosomonas eutropha D23

Start the discussion